Cite
The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*.
MLA
Zhao, Y., et al. “The Efficacy and Safety of Dupilumab in Chinese Patients with Moderate‐to‐severe Atopic Dermatitis: A Randomized, Double‐blind, Placebo‐controlled Study*.” British Journal of Dermatology, vol. 186, no. 4, Apr. 2022, pp. 633–41. EBSCOhost, https://doi.org/10.1111/bjd.20690.
APA
Zhao, Y., Wu, L., Lu, Q., Gao, X., Zhu, X., Yao, X., Li, L., Li, W., Ding, Y., Song, Z., Liu, L., Dang, N., Zhang, C., Liu, X., Gu, J., Wang, J., Geng, S., Liu, Q., Guo, Y., & Dong, L. (2022). The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*. British Journal of Dermatology, 186(4), 633–641. https://doi.org/10.1111/bjd.20690
Chicago
Zhao, Y., L. Wu, Q. Lu, X. Gao, X. Zhu, X. Yao, L. Li, et al. 2022. “The Efficacy and Safety of Dupilumab in Chinese Patients with Moderate‐to‐severe Atopic Dermatitis: A Randomized, Double‐blind, Placebo‐controlled Study*.” British Journal of Dermatology 186 (4): 633–41. doi:10.1111/bjd.20690.